 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.             *hb0027*      
HOUSE BILL 27  
J1, C2    6lr1106  
  (PRE –FILED)  CF 6lr1806  
By: Delegate Wims  
Requested: October 7, 2025  
Introduced and read first time: January 14, 2026  
Assigned to: Health  
 
A BILL ENTITLED  
 
AN ACT concerning  1 
 
Maryland Technology Development Corporation – Long COVID  Innovation 2 
Grant and Loan Program  3 
 
FOR the purpose of requiring the Maryland Technology Development Corporation to 4 
establish a grant and loan program to provide grants and loans for Long COVID 5 
innovation ; requiring the Corporation  to contract with an independent review 6 
committee composed of scientific experts in the field of Long COVID; establishing 7 
the Maryland Long COVID Research Fund under the administration of the 8 
Corporation as a special, nonlapsing fund;  requiring that the interest earnings of the 9 
Fund be credited to the Fund; and generally relating to a Long COVID grant and 10 
loan program . 11 
 
BY repealing and reenacting, without amendments,  12 
 Article – Economic Development  13 
Section 10 –401(a) and (c)  14 
 Annotated Code of Maryland  15 
 (2024 Replacement Volume and 2025 Supplement)  16 
 
BY adding to  17 
 Article – Economic Development  18 
Section 10 –4E–01 through 10–4E–07 to be under the new subtitle “Subtitle 4E. Long 19 
COVID Innovation Grant and Loan Program ” 20 
 Annotated Code of Maryland  21 
 (2024 Replacement Volume and 2025 Supplement)  22 
 
BY repealing and reenacting, without amendments,  23 
 Article – State Finance and Proc urement  24 
Section 6 –226(a )(2)(i)  and (ii)  25 
 Annotated Code of Maryland  26 
 (2021 Replacement Volume and 2025 Supplement)  27 
2 HOUSE BILL 27   
 
  
BY repealing and reenacting, with amendments,  1 
 Article – State Finance and Procurement  2 
Section 6 –226(a)(2)( iii)212. and 213. 3 
 Annotated Code  of Maryland  4 
 (2021 Replacement Volume and 2025 Supplement)  5 
 
BY adding to  6 
 Article – State Finance and Procurement  7 
Section 6 –226(a)(2)(ii i)214. 8 
 Annotated Code of Maryland  9 
 (2021 Replacement Volume and 2025 Supplement)  10 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 11 
That the Laws of Maryland read as follows:  12 
 
Article – Economic Development  13 
 
10–401. 14 
 
 (a) In this subtitle the following words have the meanings indicated.  15 
 
 (c) “Corporation” means the Maryland Technology Development Corporation.  16 
 
SUBTITLE 4E. LONG COVID  INNOVATION GRANT AND LOAN PROGRAM . 17 
 
10–4E–01. 18 
 
 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS 19 
INDICATED . 20 
 
 (B) “COMMITTEE ” MEANS THE INDEPENDEN T SCIENTIFIC PEER RE VIEW 21 
COMMITTEE WITH WHICH THE CORPORATION CONTRACTS UNDER § 10–4E–04 OF 22 
THIS SUBTITLE . 23 
 
 (C) “CORPORATION ” HAS THE MEANING STAT ED IN § 10–401 OF THIS TITLE . 24 
 
 (D) “FUND” MEANS THE MARYLAND LONG COVID  RESEARCH FUND. 25 
 
 (E) “LONG COVID”  HAS  THE MEANING : 26 
 
  (1) ESTABLISHED BY THE NATIONAL ACADEMY OF SCIENCES IN  “A 27 
LONG COVID  DEFINITION : A CHRONIC , SYSTEMIC DISEASE STATE WITH 28 
PROFOUND CONSEQUENCES ” PUBLISH ED IN 2024 ; OR 29 
 
 HOUSE BILL 27  3 
 
   (2) IF THE NATIONAL ACADEMY OF SCIENCES SUBSEQUENTLY  1 
AMENDS  THE DEFINITION , THE MEANING MOST RECENTL Y ESTABLISHED AND 2 
PUBLISHED BY THE NATIONAL ACADEMY OF SCIENCES . 3 
 
 (F) “LONG COVID  INNOVATION ” MEANS RESEARCH , PRODUCT 4 
DEVELOPMENT , AND MANUFACTURING IN  THE STATE  RELATED TO TREATMENT OF 5 
LONG COVID  AND CONDUCTED WITH M ONEY FROM THE FUND. 6 
 
 (G) “PROGRAM ” MEANS THE GRANT AND LOAN PROGRAM ESTABLISHED BY 7 
THE CORPORATION UNDER § 10–4E–02 OF THIS SUBTITLE . 8 
 
10–4E–02. 9 
 
 THE CORPORATION SHALL EST ABLISH A GRANT AND L OAN PROGRAM TO 10 
PROVIDE GRANTS AND L OANS FOR STATE–FUNDED  LONG COVID  INNOVATION . 11 
 
10–4E–03. 12 
 
 (A) THE CORPORATION SHALL : 13 
 
  (1) DEVELOP CRITERIA , STANDARDS , AND REQUIREMENTS FOR  THE 14 
REVIEW OF APPLICATIONS FOR A PROGRAM GRANT OR LOAN ; 15 
 
  (2) REVIEW , EVALUATE , RANK , AND RATE RESEARCH PR OPOSALS FOR 16 
STATE–FUNDED LONG COVID  INNOVATION GRANTS AND LOANS BASED ON THE 17 
PROCEDURES AND GUIDE LINES ESTABLISHED BY T HE CORPORATION ; 18 
 
  (3) BASED ON RECOMMENDAT IONS OF THE COMMITTEE , AWARD AND 19 
DISBURSE GRANTS AND LOANS FROM THE FUND; 20 
 
  (4) ESTABLISH STANDARDS FOR THE OVERSIGHT AN D USE OF GRANTS 21 
AND LOANS  AWARDED UNDER THE PR OGRAM ; 22 
 
  (5) CONDUCT PROGRESS OVE RSIGHT REVIEWS OF GR ANT AND LOAN 23 
RECIPIENTS AND RESCI ND FUNDS IF THE CORPORATION DETERMINES THAT A 24 
GRANT RECIPIENT IS FAIL ING TO MEET THE ESTABLIS HED GOALS FOR THE FUNDED  25 
PROJECT ; AND 26 
 
  (6) DEVELOP POLICIES AND  PROCEDURES GOVERNING  CON FLICTS 27 
OF INTEREST BY COMMITTEE MEMBERS , INCLUDING POLICIES A ND PROCEDURES 28 
FOR DISCLOSURE AND R ECUSAL . 29 
 
4 HOUSE BILL 27   
 
  (B) THE CORPORATION MAY CONSU LT WITH EXPERTS IN P ERFORMING ITS 1 
DUTIES . 2 
 
10–4E–04. 3 
 
 (A) THE CORPORATION SHALL CON TRACT WITH AN INDEPE NDENT REVIEW 4 
COMMITTEE COMPOSED O F SCIENTIFIC EXPERTS  IN THE FIELD OF LONG COVID  5 
INNOVATION . 6 
 
 (B) THE COMMITTEE SHALL : 7 
 
  (1) REVIEW , EVALUATE , RANK , AND RATE RESEARCH PR OPOSALS FOR 8 
STATE–FUNDED LONG COVID  INNO VATION : 9 
 
   (I) BASED ON THE PROCEDU RES AND GUIDELINES 10 
ESTABLISHED BY THE CORPORATION ; AND 11 
 
   (II) IN A MANNER THAT GIV ES DUE CONSIDERATION  TO THE 12 
SCIENTIFIC , MEDICAL , AND ETHICAL IMPLICAT IONS OF THE RESEARCH ; AND 13 
 
  (2) BASED ON THE RANKING S AND RATINGS AWARDED TO THE 14 
RESEARCH PROPOSALS , MAKE RECOMMENDATIONS  TO THE CORPORATION FOR THE 15 
AWARD AND DISBURSEME NT OF GRANTS AND LOA NS. 16 
 
 (C) A MEMBER OF THE COMMITTEE : 17 
 
  (1) IS NOT ELIGIBLE TO R ECEIVE A GRANT OR LO AN FOR  18 
STATE–FUNDED LONG COVID  INNOVATION FROM T HE FUND; AND 19 
 
  (2) SHALL BE SUBJECT TO THE  POLICIES AND PROCEDU RES 20 
GOVERNING CONFLICT S OF INTEREST  ESTABLISHED BY THE CORPORATION UNDER 21 
§ 10–4E–03(A)(6) OF THIS SUBTITLE . 22 
 
10–4E–05. 23 
 
 (A) THERE IS A MARYLAND LONG COVID  RESEARCH FUND. 24 
 
 (B) THE PURPOSE OF THE FUND IS TO PROMOTE STATE–FUNDED LIFE 25 
SCIENCES RESEARCH , DEVELOPMENT , COMMERCIALIZATION , AND 26 
MANUFACTURING IN THE  STATE RELATED TO LONG COVID  THROUGH GRANTS AND 27 
LOANS TO PUBLIC AND PRIVATE ENTITIES IN THE STATE . 28 
 
 (C) THE CORPORATION SHAL L ADMINISTER THE FUND. 29 
 HOUSE BILL 27  5 
 
  
 (D) (1) THE FUND IS A SPECIAL , NONLAPSING FUND THAT  IS NOT 1 
SUBJECT TO § 7–302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE . 2 
 
  (2) THE STATE TREASURER SHALL HOLD THE FUND SEPARATELY , 3 
AND THE COMPTROLLER SHALL ACC OUNT FOR THE FUND. 4 
 
 (E) THE FUND CONSISTS OF : 5 
 
  (1) MONEY APPROPRIATED I N THE STATE BUDGET TO THE FUND; 6 
 
  (2) INTEREST EARNINGS OF  THE FUND; AND 7 
 
  (3) ANY OTHER MONEY FROM  ANY OTHER SOURCE ACC EPTED FOR 8 
THE BENEFIT OF THE FUND. 9 
 
 (F) MONEY IN THE FUND MAY BE USED ONLY  TO: 10 
 
  (1) AWARD GRANTS AND LOA NS FOR STATE–FUNDED LONG COVID  11 
INNOVATION ; AND 12 
 
  (2) PAY THE COSTS NECESS ARY TO ADMINISTER TH E FUND. 13 
 
 (G) (1) THE STATE TREASURER SHALL INVES T THE MONEY IN THE FUND 14 
IN THE SAME MANNER A S OTHER STATE MONEY MAY BE IN VESTED . 15 
 
  (2) ANY INTEREST EARNINGS  OF THE FUND SHALL BE CREDITE D TO 16 
THE FUND. 17 
 
 (H) (1) EACH FISCAL YEAR , THE GOVERNOR MAY INCLUDE IN THE 18 
ANNUAL BUDGET BILL A N APPROPRIATION TO T HE FUND. 19 
 
  (2) EXPENDITURES FROM THE  FUND MAY BE MADE ONLY  IN 20 
ACCORDANCE WITH THE STAT E BUDGET . 21 
 
10–4E–06. 22 
 
 THE CORPORATION SHALL ADO PT REGULATIONS TO : 23 
 
  (1) ESTABLISH PROCEDURES  FOR AWARDING AND MAK ING THE 24 
DISBURSEMENT OF A GR ANT OR LOAN  UNDER THE PROGRAM ; 25 
 
6 HOUSE BILL 27   
 
   (2) ESTABLISH POLICIES ADDRESSING  CONFLICTS OF INTERES T FOR 1 
MEMBERS OF THE COMMITTEE ; AND 2 
 
  (3) CARRY OUT ITS DUTIES  UNDER THIS SUBTITLE . 3 
 
10–4E–07. 4 
 
 (A) ON OR BEFORE JANUARY 1 EACH YEAR , THE CORPORATION SHALL 5 
REPORT TO THE GOVERNOR AND , IN ACCORDANCE WITH § 2–1257  OF THE STATE 6 
GOVERNME NT ARTICLE , THE GENERAL ASSEMBLY ON THE PROGR ESS OF THE 7 
LONG COVID  INNOVATION CONDUCTED WITH GRANT S OR LOANS AWARDED U NDER 8 
THE PROGRAM . 9 
 
 (B) THE REPORT SHALL IDEN TIFY: 10 
 
  (1) EACH RECIPIENT OF A GRANT OR LOAN  AWARDED UNDER THE 11 
PROGRAM ; 12 
 
  (2) THE AMOUNT OF FUNDING  AWARDED TO EACH RECI PIENT ; 13 
 
  (3) A DESCRIPTION OF THE  TYPE OF STATE–FUNDED LONG COVID  14 
INNOVATION CONDUCTED BY THE RECIPIENT ; 15 
 
  (4) INDICATORS OF THE EC ONOMIC IMPACT OF  GRANTS AND LOANS 16 
MADE FROM  THE FUND; AND 17 
 
  (5) ANY RECOMMENDATIONS  FOR IMPROVING THE OV ERALL 18 
EFFECTIVENESS OF THE  PROGRAM . 19 
 
Article – State Finance and Procurement  20 
 
6–226. 21 
 
 (a) (2) (i) This paragraph does not apply in fiscal years 2024 through 2028.  22 
 
   (ii) Notwithstanding any other provision of law, and  unless 23 
inconsistent with a federal law, grant agreement, or other federal requirement or with the 24 
terms of a gift or settlement agreement, net interest on all State money allocated by the 25 
State Treasurer under this section to special funds or accounts, an d otherwise entitled to 26 
receive interest earnings, as accounted for by the Comptroller, shall accrue to the General 27 
Fund of the State.  28 
 
   (iii) The provisions of subparagraph (ii) of this paragraph do not 29 
apply to the following funds:  30 
 HOUSE BILL 27  7 
 
  
    212. the Depart ment of Social and Economic Mobility Special 1 
Fund; [and] 2 
 
    213. the Population Health Improvement Fund ; AND 3 
 
    214. THE MARYLAND LONG COVID  RESEARCH FUND . 4 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July 5 
1, 2026.  6 